Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Raised by Swiss National Bank

Swiss National Bank lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 437,500 shares of the biopharmaceutical company’s stock after buying an additional 3,200 shares during the quarter. Swiss National Bank owned about 0.15% of Amicus Therapeutics worth $4,121,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in FOLD. KBC Group NV lifted its stake in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,120 shares during the last quarter. Legacy Capital Group California Inc. raised its holdings in shares of Amicus Therapeutics by 20.2% during the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 3,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at $55,000. China Universal Asset Management Co. Ltd. boosted its holdings in Amicus Therapeutics by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock worth $597,000 after purchasing an additional 6,314 shares in the last quarter. Finally, Diversified Trust Co increased its position in Amicus Therapeutics by 9.7% during the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock worth $770,000 after buying an additional 7,257 shares during the last quarter.

Amicus Therapeutics Trading Down 0.8 %

Shares of FOLD stock opened at $8.62 on Wednesday. The firm has a market capitalization of $2.65 billion, a P/E ratio of -47.89, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1 year low of $8.52 and a 1 year high of $12.65. The firm’s fifty day simple moving average is $9.33 and its 200 day simple moving average is $10.01. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.